Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.: Active Tau immunotherapy

Laëticia Troquier 1 Raphaëlle Caillierez 1 Sylvie Burnouf 1 Francisco Fernandez-Gomez 1 Marie-Eve Grosjean 1 Nadège Zommer 1 Nicolas Sergeant 1 Susanna Schraen-Maschke 1 David Blum 1 Luc Buee 1, *
* Auteur correspondant
1 Centre de recherche Jean-Pierre Aubert-Neurosciences et Cancer
Abstract : Recent data indicate that Tau immunotherapy may be relevant for interfering with neurofibrillary degeneration in Alzheimer disease and related disorders referred to as Tauopathies. The key question for immunotherapy is the choice of the epitope to target. Abnormal phosphorylation is a well-described post-translational modification of Tau proteins and may be a good target. In the present study, we investigated the effects of active immunization against the pathological epitope phospho-Ser422 in the THY-Tau22 transgenic mouse model. Starting from 3-6 months of age, THY-Tau22 mice develop hippocampal neurofibrillary tangle-like inclusions and exhibit phosphorylation of Tau on several AD-relevant Tau epitopes. Three month-old THY-Tau22 mice were immunized with a peptide including the phosphoserine 422 residue while control mice received the adjuvant alone. A specific antibody response against the phospho-Ser422 epitope was observed. We noticed a decrease in insoluble Tau species (AT100- and pS422 immunoreactive) by both biochemical and immunohistochemical means correlated with a significant cognitive improvement using the Y-maze. This Tau immunotherapy may facilitate Tau clearance from the brain toward the periphery since, following immunization, an increase in Tau concentrations was observed in blood. Overall, the present work is, to our knowledge, the first one to demonstrate that active immunotherapy targeting a real pathological epitope such as phospho-Ser422 epitope is efficient. This immunotherapy allows for Tau clearance and improves cognitive deficits promoted by Tau pathology in a well-defined Tau transgenic model.
Keywords : Alzheimer immunotherapy neurofibrillary degeneration transgenic mouse model Tau proteins
Type de document :
Article dans une revue
Curr Alzheimer Res, 2012, 9 (4), pp.397-405
Liste complète des métadonnées

Littérature citée [48 références]  Voir  Masquer  Télécharger
http://www.hal.inserm.fr/inserm-00664452
Contributeur : Luc Buee <>
Soumis le : mercredi 30 janvier 2013 - 07:00:09
Dernière modification le : samedi 7 avril 2018 - 14:40:02
Document(s) archivé(s) le : jeudi 30 mars 2017 - 23:30:16

Fichiers

TroquierLastVersion.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

  • HAL Id : inserm-00664452, version 1
  • PUBMED : 22272619

Collections

Citation

Laëticia Troquier, Raphaëlle Caillierez, Sylvie Burnouf, Francisco Fernandez-Gomez, Marie-Eve Grosjean, et al.. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.: Active Tau immunotherapy. Curr Alzheimer Res, 2012, 9 (4), pp.397-405. 〈inserm-00664452〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

211

Téléchargements de fichiers

1230

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD